Pleasanton, California - Boster Bio Technology unlocks insights into cancer and neurological disorders with high-quality ...

Thus, in the present study, we aimed to generate a new class of therapeutics based on a recombinant single-domain antibody (sdAb) immunotoxin derived from the PE38 Pseudomonas aeruginosa exotoxin A.

Addgene is thrilled to have the expertise of this group of leaders in life sciences and technology as part of our management team and Board of Directors – a testament to the value of our vision for a ...

Despite the therapeutic benefits of IgM antibodies a major technological drawback has been identified in comparison to the classical IgG molecule. Recombinant production of this immunoglobulin class ...

Transient recombinant expression of antibodies was achieved by co-transfecting paired heavy and light chain expression plasmids into suspension cultures of Expi293F cells according to manufacturer’s ...

Many biologics, such as monoclonal antibodies, are recombinant protein therapies. Diverse ultra-long CDRs can be swapped on the same antibody scaffold with minimal impact on scaffold structure and ...

FDA approves Biocon Biologics' Jobevne, a biosimilar Bevacizumab for cancer treatment, expanding access to affordable biologics.

In 2023, bevacizumab sales in the U.S. were around $2.0 billion. Biocon Biologics serves over 5 million patients each year across its global operations.

The global cell culture market is projected to grow at a CAGR of 12% from 2025 to 2030. This growth is driven by increasing ...